ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Merck KGaA's Merck Serono division is spending some $375 million to expand its production site in Corsier-sur-Vevey, Switzerland. The project will allow the company to boost output of Erbitux, the cancer-fighting monoclonal antibody that it markets with ImClone Systems. By 2010, Merck will add two production suites with a combined 120,000 L of bioreactor capacity.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter